Genetic Counseling

Formal Hereditary Cancer Genetic Counseling Improves Patient Outcomes
Anaheim, CA—The speed at which the genetics revolution has propelled forward in oncology has created enormous ramifications and unanticipated challenges, according to Suzanne Mahon, RN, DNSc, AOCN, AGN-BC, CNS, Professor, Division of Hematology/Oncology, Department of Internal Medicine, Saint Louis University, MO. Read More ›

DNA Repair Targeted Therapy: Expanding Options for Patients with Cancer
The past year has been an exciting time for medical applications of genetic testing. We are entering an era when germline genetic status is no longer focused solely on risk stratification to guide surveillance and risk-reducing options, but is increasingly influencing treatment selection. Read More ›

Addressing the Needs of Previvors Struggling to Access Screening and Recommended Interventions

In 2010, FORCE: Facing Our Risk of Cancer Empowered successfully spearheaded passage of a congressional resolution declaring the first-ever National Hereditary Breast and Ovarian Cancer week.

Read More ›

Variants of Uncertain Significance—Frequently Asked Questions

Cristi Radford, MS, CGC, and Michele Gabree, MS, CGC, explain what variants of uncertain significance are, and address some of the questions that are frequently asked by providers.

Read More ›

New Criteria for Inherited Prostate Cancer Genetic Testing

Similar to other disease sites, prostate cancer has seen a surge in genetic testing options. To help address the role of genetic testing in prostate cancer disease management, the NCCN Clinical Practice Guidelines in Oncology were updated in February 2018 to include germline recommendations.

Read More ›

Lynch syndrome is a hereditary cancer syndrome that places individuals at an increased risk for colorectal, endometrial, stomach, ovarian, urothelial, and other cancers. Read More ›

PARP inhibitors were the first class of drugs specifically developed to treat BRCA-related tumors by targeting the DNA repair pathway. Although they were developed more than a decade ago, the FDA only granted approval for their clinical use a few years ago. Read More ›

Screening of colorectal cancer (CRC) tumors for mismatch repair (MMR) deficiency has been shown to increase the identification of patients with Lynch syndrome. Read More ›

Parents with inherited cancer mutations often wonder when to disclose results to their children and what affect it will have on them. Read More ›

Page 1 of 5

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: